Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas Receiving Bendamustine and Rituximab

Hematological Oncology - United Kingdom
doi 10.1002/hon.2439_128
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Study of Gene Polymorphisms as Predictors of Treatment Efficacy and Toxicity in Patients With Indolent Non-Hodgkin Lymphomas and Mantle Cell Lymphoma Receiving Bendamustine and Rituximab

British Journal of Haematology
Hematology
2018English

A Phase II Study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent Non-Follicular Non-Hodgkin Lymphoma

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2016English

Chronic Hepatitis E in Patients With Indolent Lymphoma After Treatment With Rituximab and Bendamustine

Hepatology
MedicineHepatology
2018English

Pegfilgrastim in Primary Prophylaxis of Febrile Neutropenia Following Frontline Bendamustine Plus Rituximab Treatment in Patients With Indolent Non-Hodgkin Lymphoma: A Single Center, Real-Life Experience

Supportive Care in Cancer
Oncology
2016English

Characteristics and Management of Rash Following Lenalidomide and Rituximab in Patients With Untreated Indolent Non-Hodgkin Lymphoma

Haematologica
Hematology
2015English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2016English

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Bendamustine-Based Therapy as First-Line Treatment for Non-Hodgkin Lymphoma

Medical Oncology
MedicineCancer ResearchOncologyHematology
2014English

Cost-Effectiveness Analysis of Bendamustin-Rituximab Compared to Chop-Rituximab in the Treatment of Indolent Follicular Non-Hodgkin Lymhoma in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy